Anti-tuberculosis drugs were stopped and then rechallenged in 177/315 (56.2%) patients with different doses, of whom 128/177 (72.3%) developed re-introduction reactions, 26/177 (14.7%) had no recurrence of ADR symptoms and the remaining (23 patients, 13%) had unclear reactions.